Medicamen Organics (NSE:MEDIORG) Debt-to-Asset : 0.33 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Medicamen Organics Debt-to-Asset?

Medicamen Organics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹125.0 Mil. Medicamen Organics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹1.6 Mil. Medicamen Organics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ₹385.8 Mil. Medicamen Organics's debt to asset for the quarter that ended in Mar. 2024 was 0.33.

Medicamen Organics Debt-to-Asset Historical Data

The historical data trend for Medicamen Organics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicamen Organics Debt-to-Asset Chart

Medicamen Organics Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Debt-to-Asset

0.36

0.37

0.36

0.33

Medicamen Organics Semi-Annual Data
	Mar21	Mar22	Mar23	Sep23	Mar24
Debt-to-Asset	0.36	0.37	0.36	0.31	0.33

Competitive Comparison of Medicamen Organics's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Organics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicamen Organics's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicamen Organics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Medicamen Organics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Medicamen Organics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Medicamen Organics's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(124.951	+	1.614)	/	385.807
	=	0.33

Medicamen Organics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(124.951	+	1.614)	/	385.807
	=	0.33

Medicamen Organics (NSE:MEDIORG) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Medicamen Organics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Medicamen Organics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicamen Organics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicamen Organics Ltd (NSE:MEDIORG) » Definitions » Debt-to-Asset

Traded in Other Exchanges

N/A

Address

Ashok Vihar Phase II, 10, Community Center No. 2, New Delhi, IND, 110052

Website

https://www.medicamenorganics.com

Medicamen Organics Ltd is engaged in developing, manufacturing, and distribution of broad range of pharmaceutical dosages including generic dosages in the form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders for government and private institutions as contract manufacturer/third party manufacturer. The company markets its product to private pharma companies in domestic as well as international markets through third-party distributors or on a loan license basis.

Medicamen Organics Headlines

No Headlines